- Home
- SWVL vs MAIA Comparison
SWVL vs MAIA Comparison
Compare SWVL & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWVL
- MAIA
- Stock Information
- Founded
- SWVL 2017
- MAIA 2018
- Country
- SWVL United Arab Emirates
- MAIA United States
- Employees
- SWVL N/A
- MAIA N/A
- Industry
- SWVL Business Services
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- SWVL Consumer Discretionary
- MAIA Health Care
- Exchange
- SWVL Nasdaq
- MAIA Nasdaq
- Market Cap
- SWVL 44.5M
- MAIA 46.7M
- IPO Year
- SWVL N/A
- MAIA 2022
- Fundamental
- Price
- SWVL $4.37
- MAIA $1.79
- Analyst Decision
- SWVL
- MAIA
- Analyst Count
- SWVL 0
- MAIA 0
- Target Price
- SWVL N/A
- MAIA N/A
- AVG Volume (30 Days)
- SWVL 6.5K
- MAIA 371.3K
- Earning Date
- SWVL 07-01-2025
- MAIA 08-08-2025
- Dividend Yield
- SWVL N/A
- MAIA N/A
- EPS Growth
- SWVL N/A
- MAIA N/A
- EPS
- SWVL N/A
- MAIA N/A
- Revenue
- SWVL $17,207,362.00
- MAIA N/A
- Revenue This Year
- SWVL N/A
- MAIA N/A
- Revenue Next Year
- SWVL N/A
- MAIA N/A
- P/E Ratio
- SWVL N/A
- MAIA N/A
- Revenue Growth
- SWVL N/A
- MAIA N/A
- 52 Week Low
- SWVL $2.40
- MAIA $1.40
- 52 Week High
- SWVL $8.25
- MAIA $4.24
- Technical
- Relative Strength Index (RSI)
- SWVL 51.73
- MAIA 47.69
- Support Level
- SWVL $3.95
- MAIA $1.66
- Resistance Level
- SWVL $4.45
- MAIA $1.95
- Average True Range (ATR)
- SWVL 0.21
- MAIA 0.10
- MACD
- SWVL -0.08
- MAIA -0.00
- Stochastic Oscillator
- SWVL 44.68
- MAIA 23.28
About SWVL Swvl Holdings Corp
Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.